Sai Parenterals Ltd has announced its initial public offering (IPO) price band at ₹372–₹392 per share. The pharmaceutical company aims to raise capital to strengthen manufacturing capacity, expand product lines, and reduce debt, positioning itself for growth in India’s competitive healthcare sector.
The IPO will open for subscription later this month, offering investors an opportunity to participate in the company’s expansion strategy. Sai Parenterals, known for its injectable formulations and parenteral drugs, plans to use the proceeds to enhance production efficiency and broaden its domestic and export reach.
IPO Details
The price band of ₹372–₹392 reflects the company’s valuation strategy, balancing investor interest with long-term growth prospects. Market analysts expect strong demand given the rising focus on affordable healthcare and the company’s established presence in the pharmaceutical supply chain.
Strategic Outlook
Sai Parenterals intends to allocate funds toward upgrading manufacturing facilities, investing in research and development, and strengthening distribution networks. The IPO is also expected to improve liquidity and provide financial flexibility for future projects.
Key Highlights
-
IPO price band set at ₹372–₹392 per share
-
Funds to be used for capacity expansion and debt reduction
-
Focus on injectable formulations and parenteral drugs
-
Company aims to strengthen domestic and export presence
-
Analysts expect strong investor interest in healthcare-focused IPO
Sources: Business Standard, Moneycontrol, Economic Times, Company filings